Clinical Trials

847 enrolled 19 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01190930 2026-05-22

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

9,350 enrolled 51 charts

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04181827 2026-05-11

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT02883049 2026-05-04

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

5,949 enrolled 28 charts

Lymphoid

Burkitt Lymphoma

NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 1 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04246047 2026-04-23

DREAMM 7

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

72 enrolled 10 charts

Multiple Myeloma

NCT06868667 2026-04-23

DREAMM 7

24 enrolled 10 charts

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT04162210 2026-03-31

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT00343460 2026-03-02

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

1,428 enrolled 21 charts

Nausea, Vomiting

NCT00400946 2026-02-13

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

800 enrolled 22 charts

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT03275285 2026-02-09

IKEMA

302 enrolled 38 charts 1 FDA

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04655144 2026-01-07

Dex-Fib

42 enrolled 9 charts

Leiomyoma

NCT03180736 2025-12-19

EMN14

304 enrolled 19 charts 1 FDA

Multiple Myeloma

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

416 enrolled 28 charts 2 FDA

Amyloidosis

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

245 enrolled 15 charts 1 FDA

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

737 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT03367572 2025-09-25

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

1,363 enrolled 20 charts

Breast

Breast Neoplasms

NCT00532155 2025-09-10

VITAL

913 enrolled 16 charts

Carcinoma, Lung Neoplasms

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

706 enrolled 29 charts

Multiple Myeloma

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

62 enrolled 16 charts

Gynecologic

Gynecologic Cancer

NCT06956170 2025-06-11

DREAMM 8

21 enrolled 9 charts

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

466 enrolled 33 charts 1 FDA

Multiple Myeloma

NCT02076009 2025-05-01

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

569 enrolled 18 charts

Multiple Myeloma

NCT00408005 2025-04-20

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

1,895 enrolled 16 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02541383 2025-04-13

Cassiopeia

1,085 enrolled 22 charts 1 FDA

Multiple Myeloma

NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

690 enrolled 17 charts

Tumor-Agnostic

Neoplasms

NCT04786964 2025-04-02

CONTERNO

25 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04484623 2025-03-18

DREAMM 8

302 enrolled 10 charts

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

256 enrolled 13 charts

Multiple Myeloma

NCT03839940 2025-01-29

MIST

39 enrolled 18 charts

Tumor-Agnostic

Neoplasms

NCT02990338 2025-01-17

ICARIA-MM

307 enrolled 32 charts 1 FDA

Multiple Myeloma

NCT02578680 2024-09-20

MK-3475-189

616 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03110562 2024-08-21

BOSTON

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03859427 2024-08-13

ARROW2

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT00557193 2024-07-15

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

218 enrolled 21 charts

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04907227 2024-07-12

KEYNOTE-921

81 enrolled 19 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03950674 2024-06-10

MK-3475-189

40 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

111 enrolled 23 charts 1 FDA

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00381680 2024-03-26

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

275 enrolled 14 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03151811 2024-01-30

OCEAN

495 enrolled 15 charts

Multiple Myeloma

NCT00078949 2023-08-23

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

849 enrolled 13 charts

Lymphoid

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT02755597 2023-08-22

Bellini

291 enrolled 24 charts

Multiple Myeloma

NCT01850524 2023-07-21

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

705 enrolled 30 charts